BGDO | Belgian Group of Digestive Oncology

  • Plein écran
  • Ecran large
  • Ecran étroit
  • Increase font size
  • Default font size
  • Decrease font size

Petacc 6

E-mail Print PDF

PETACC 6 is a large intergroup study coordinated by the EORTC studying preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer.

The BGDO participates as one of the European groups to the PETACC (Pan European Trials Adjuvant Colon Cancer)-6 trial. ln the PETACC-6 trial patients with locally advanced non-metastatic rectal cancer are randomized between 2 preoperative regimens of chemoradiotherapy: capecitabine plus radiotherapy or capecitabine plus oxaliplatin and radiotherapy.

Patients receive an irradiation of 45 + 5.4 Gy in fractions of 1.8 Gy. The preoperative chemoradiotherapy is followed approximately 6 weeks later by optimal surgery: Total Mesorectal Excision.

After the operation a postoperative chemotherapy is continued with either capecitabine or capecitabine plus oxaliplatin for 6 cycles.

On January 10, 2011, 634 patients were included internationally of which 125 in Belgium.

Twelve BGDO centers are active and have recruited until now patients. The total sample size for the trial is 1090 patients.

For further information contact: This e-mail address is being protected from spambots. You need JavaScript enabled to view it   or  This e-mail address is being protected from spambots. You need JavaScript enabled to view it